(photo: )

Takeda invests €100m in German dengue vaccine plant

Japan’s Takeda Pharmaceuticals will invest more than EUR 100 million to build a new manufacturing plant for its dengue vaccine candidate in Singen, Germany.


  •  (photo: )

    New R&D platform puts focus on nanotechnology

    Ferring Pharmaceuticals and Aché Laboratórios Farmacêuticos have struck a long-term collaboration focused on improving the bioavailability, efficacy and safety profile of oral therapeutics through nanotechnology.






 (photo: )

EMA revising guideline on first-in-human clinical trials

The European Medicines Agency (EMA), in cooperation with the European Commission and the Member States of the European Union, is proposing changes to its existing guideline on first-in-human clinical trials, to further improve the safety of trial participants.

 (photo: )

NICE approves life-extending breast cancer drug in draft guidance

People with advanced breast cancer are set to benefit from a life-extending drug as NICE says it should be available on the NHS.


 (photo: )

TraceLink raises $51m to accelerate pharma track & trace

TraceLink, a track and trace network for connecting the life sciences supply chain and eliminating counterfeit prescription drugs from the global marketplace, has raised $51.5 million in Series C financing.

 (photo: )

Yorkshire pharma firm targets overseas medicine exports

A new medicines and pharmaceuticals wholesaler and distributor has been launched to solve difficulties faced by millions of people in Iraq in obtaining modern medicines to treat many illnesses effectively.


 (photo: )

Pharmalink gains EU orphan status for kidney disease treatment

The European Commission has granted Orphan Medicinal Product designation in the EU to Pharmalink’s Nefecon (budesonide).

 (photo: )

Chugai & Berlin-Chemie enter license agreement for anti-cancer agent

Japan’s Chugai Pharmaceutical Co and Berlin-Chemie Menarini (of the Menarini Group) have entered into a global license agreement for PA799, class I PI3K inhibitor.